TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02963454

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microdialysis Probe (Muscle microdialysis)
Description: Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were determined at baseline and then every six hours for the following 72 hours after randomization.~During the study period, conventional treatment was continued as per usual practice. Fluid challenges were performed, and repeated as necessary, to maintain central venous pressure (CVP) ≥8 and pulmonary arterial occlusion pressure (PAOP) ≥12 mmHg. Norepinephrine was titrated to maintain mean arterial pressure (MAP) ≥65 mmHg. Packed red blood cells were transfused when Hemoglobin (Hb) concentrations decreased below 7 g/dL, or if the patient exhibited clinical signs of inadequate systemic oxygen supply.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microdialysis Probe (Muscle microdialysis)
Description: Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were determined at baseline and then every six hours for the following 72 hours after randomization.~During the study period, conventional treatment was continued as per usual practice. Fluid challenges were performed, and repeated as necessary, to maintain central venous pressure (CVP) ≥8 and pulmonary arterial occlusion pressure (PAOP) ≥12 mmHg. Norepinephrine was titrated to maintain mean arterial pressure (MAP) ≥65 mmHg. Packed red blood cells were transfused when Hemoglobin (Hb) concentrations decreased below 7 g/dL, or if the patient exhibited clinical signs of inadequate systemic oxygen supply.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dobutamine
Description: Dobutamine (5 μg/kg/min) will be used as indicated
Study: NCT01733537

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Both arms will receive brief, basic education about recommended measures to increase their visibility
Study: NCT02963454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: Levosimendan (0.2 μg/kg/min) will be used as indicated
Study: NCT03526744

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: marine protein hydrolysate 1234
Description: Dietary Supplement for e.g. in this order: MPH 1600 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 800 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 2400 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 3200 mg for 7 days, than 7 days wash-out.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: marine protein hydrolysate 2134
Description: Dietary Supplement for e.g. in this order: MPH 3200 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 800 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 2400 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 1600 mg for 7 days, than 7 days wash-out.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: marine protein hydrolysate 3124
Description: Dietary Supplement for e.g. in this order: MPH 2400 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 3200 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 1600 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 800 mg for 7 days, than 7 days wash-out.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: marine protein hydrolysate 4123
Description: Dietary Supplement for e.g. in this order: MPH 1600 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 800 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 3200 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 2400 mg for 7 days, than 7 days wash-out.
Study: NCT01307384

Intervention type: DEVICE
Intervention: Continuum Metal on Polyethylene Acetabular System
Description: Used in primary hip arthroplasty
Study: NCT02585362

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical exercise
Description: The standardized Training program will be performed twice a week in the Kantonsspital Winterthur and once a week in a home based setting

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nutrition counseling
Description: At least 3 times, participants will receive nutrition counseling to improve energy- and protein intake

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: whey protein supplement
Description: On workout days study participants will consume twice a day 15 g of the supplement powder with approximately 150 ml water. On the remaining days participants consume the supplement once a day.
Study: NCT02536027

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: continuous venovenous hemofiltration
Description: Continuous renal replacement therapy (CRRT) has become routine for patients with AKI, chronic renal failure, ﬂuid overload as well as oliguria in ICU. In clinical practice, continuous venovenous hemofiltration (CVVH) is actually the method of choice for CRRT in critically ill and hemodynamic instable patients. CVVH has significant beneficial effects on removing inflammatory cytokines, improving oxygen index, decreasing vasopressor requirements, increasing cardiac index, and regulating immune dysfunction, specifically in patients with septic shock.
Study: NCT01475877

Intervention type: DRUG
Intervention: Bromfenac
Description: Bromfenac 0.09% 1 drop in study eyes q day
Study: NCT02848222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bruder Moist Heat Compress

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bruder Moist Heat Compress

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Washcloth
Study: NCT03601260

Intervention type: DRUG
Group type: OTHER
Intervention: Allopurinol
Description: Treatment of gout patients by oral dosage of 100 mg-300mg/ day of Allopurinol
Study: NCT02947386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Given IV
Study: NCT00555724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB022
Description: IV infusion once every three weeks until disease progression or unacceptable toxicity
Study: NCT04684394

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEM103
Description: GEM103 500 mcg/50 mcL intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Aflibercept 2 mg/50 mcL (SOC) intravitreal injection~Sham intravitreal injection
Study: NCT02947386

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT00027170

Intervention type: DEVICE
Intervention: Siemens MRI scanner
Description: Investigational or research MRI coils may be used in the protocol. The coils are noninvasive devices external to the body. The coils act as antennae to receive small radiofrequency signals out of the body. Coils of the type we use are used daily in clinical MRI practice.

Intervention type: DEVICE
Intervention: Siemens MRI scanner
Description: Investigational or research MRI coils may be used in the protocol. The coils are noninvasive devices external to the body. The coils act as antennae to receive small radiofrequency signals out of the body. Coils of the type we use are used daily in clinical MRI practice.
Study: NCT01250106

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri
Description: twice daily
Study: NCT04684394

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Aflibercept
Description: Aflibercept 2 mg/50 mcL (SOC) intravitreal injection~Sham intravitreal injection
Study: NCT01250106

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus reuteri
Description: twice daily
Study: NCT03111563

Intervention type: OTHER
Group type: OTHER
Intervention: Warm saline distension media in office hysteroscopy
Description: warm saline distension media in office hysteroscopy

Intervention type: OTHER
Group type: OTHER
Intervention: Warm saline distension media in office hysteroscopy
Description: warm saline distension media in office hysteroscopy
Study: NCT00379665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 1 mg/ml at a dosage of approximately 2 mg per cubic cm of tumor. Weekly up to 6 injections.
Study: NCT04147689

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DESIRIAL® PLUS
Description: DESIRIAL® PLUS is a cross-linked hyaluronic acid gel to restore volume by filling the labia majora, to rehydrate and to add tone and tension to the area of connective tissue.~The baseline injection is performed at V1, with a maximum volume to be injected per labium of 2 ml. The exact volume will be determined by the physician in order to reach optimal volume correction.~One optional touch-up injection of DESIRIAL® PLUS is allowed at V2 (4 weeks after Baseline), with a maximum volume to be injected per labium of 1 ml. No other touch-up injections are allowed until the end of the study.
Study: NCT01205100

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bio-feedback
Description: By providing on-line electromyography information of muscle activity, patients will be able to control and actively correct their muscle activity during the 15 min treatment session. Each patients will attend 3 treatment sessions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03579940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT04519736

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single Band vs. Dual Band Pulsed Light Technology for the Treatment of Photodamage

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single Band vs. Dual Band Pulsed Light Technology for the Treatment of Photodamage
Study: NCT02252146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMO-8400
Description: MO-8400 given subcutaneously twice weekly
Study: NCT03065322

Intervention type: OTHER
Intervention: To assess risk of OSA
Description: The risk of OSA will be assessed using the Berlin questionnaire and the Epworth Sleepiness Scale (ESS). Women with at high risk of OSA will have home-based sleep studies performed. Study participants will be divided based on the results of the Berlin and ESS questionnaires and sleep studies into two groups: 1) PCOS low risk OSA: women with normal ESS and normal Berlin questionnaire (no sleep studies performed), or women with normal sleep studies; and 2) PCOS OSA: women with OSA proven by sleep studies.
Study: NCT04314908

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apical enlargement
Description: The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will be opened. The working length will be measured using apex locator and the 0 point will be based on. After standard irrigation protocol, root canals will be obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apical enlargement + Sonic Activation Assisted Irrigation
Description: The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will open. The working length will be measured using apex locator and the 0 point will be based on. After standard irrigation protocol, sonic activation assisted irrigation will be applied to the root canals. Then the teeth were obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non Apical enlargement
Description: The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will open. The working length will be measured using apex locator and 1 mm shorter than the 0 point will be based on. After standard irrigation protocol, root canals will be obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non Apical enlargement + Sonic Activation Assisted Irrigation
Description: The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will open. The working length will be measured using apex locator and 1 mm shorter than the 0 point will be based on. After standard irrigation protocol, sonic activation assisted irrigation will be applied to the root canals. Then the teeth were obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary.
Study: NCT01038141

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery for advanced haemorrhoidal disease
Description: Milligan Morgan vs Recto Anal Repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery for advanced haemorrhoidal disease
Description: Milligan Morgan vs Recto Anal Repair
Study: NCT04001413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0457
Description: MEDI0457 is an investigational drug that will be administered with the Cellectra Device in this study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is an investigational drug in this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is an investigational drug in this study.
Study: NCT03813888

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arsha Vidya chldren's Group
Description: Yoga, Vedic chants, Vedant sessions, Gita sessions and group activities within the Gurukulam (centre)

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Activity group
Description: Usual after school activities at home.
Study: NCT04290039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine Sulfate Ophthalmic Solution
Description: Atropine sulfate ophthalmic solution, USP 1% is a sterile topical anti-muscarinic indicated for cyclopegia, mydriasis, and penalization of the healthy eye in the treatment of amblyopia. Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains active ingredient: atropine sulfate 10 mg equivalent to 8.3 mg of atropine. Inactive ingredients include benzalkonium chloride 0.1 mg (0.01%), dibasic sodium phosphate, edetate disodium, hypromellose (2910), monobasic sodium phosphate, hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0), and water for injection, USP.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine Sulfate Ophthalmic Solution
Description: Atropine sulfate ophthalmic solution, USP 1% is a sterile topical anti-muscarinic indicated for cyclopegia, mydriasis, and penalization of the healthy eye in the treatment of amblyopia. Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains active ingredient: atropine sulfate 10 mg equivalent to 8.3 mg of atropine. Inactive ingredients include benzalkonium chloride 0.1 mg (0.01%), dibasic sodium phosphate, edetate disodium, hypromellose (2910), monobasic sodium phosphate, hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0), and water for injection, USP.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine Sulphate Injection
Description: Atropine sulfate injection, USP, 8mg/20mL (0.4 mg per mL) is a sterile, nonpyrogenic, isotonic, clear solution of atropine sulfate in water for injection with sodium chloride sufficient to render the solution isotonic. Each mL contains atropine sulfate, 0.4 mg; benzyl alcohol, 9 mg; sodium chloride 9 mg; and may contain sulfuric acid for pH adjustment, pH 3.5 (3.0 to 3.8).
Study: NCT01478971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin
Description: Commercially available epoetin alfa administered weekly, twice weekly, or thrice weekly at an initial starting dose, frequency of administration, and mode of administration (intravenous \[IV\] or subcutaneous \[SC\]) individually determined for each participant using the site's usual standard of care. Subsequent dose adjustments or dose holds may have been made in order to maintain a hemoglobin concentration of \<11 g/dL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginesatide
Description: Administered as a once monthly intravenous (IV) or subcutaneous (SC) injection. The initial dose of peginesatide injection was based on the final weekly dose of epoetin administered in the SCP; subsequent doses may have been adjusted in order to maintain hemoglobin concentrations at \<11 g/dL.
Study: NCT02277600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Darunavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Cobicistat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Cobicistat
Study: NCT01553903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen,
Description: Tamoxifen 20 mg/day during 5 years,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane 25mg/day during 5 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Anastrozole 1 mg/day during 5 years,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5 mg/day during 5 years,
Study: NCT01132807

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bleomycin Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procarbazine Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT04684394

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham intravitreal injection
Study: NCT02368028

Intervention type: OTHER
Intervention: Oral Samples
Description: Oral samples of saliva, dental plaque and DNA will be collected between the two groups.

Intervention type: OTHER
Intervention: Oral Samples
Description: Oral samples of saliva, dental plaque and DNA will be collected between the two groups.
Study: NCT02648490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX07
Description: recombinant human anti-EGFR monoclonal antibody against cancers
Study: NCT01132807

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo FDG PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG PET/CT
Study: NCT00610402

Intervention type: OTHER
Intervention: blood sample tear drop sample
Description: blood sample tear drop sample
Study: NCT05120427

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid based nutrient Supplements (LNS):
Description: LNS are 20 g/\~110 calorie nutrient supplements that provide energy, protein, essential fatty acids and a wide range of micronutrients critical for children ages 6 to 24 months of age. They are designed to complement diets without displacing breastmilk and local dietary preferences and can be mixed into the child's meal or eaten directly from the sachet.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid based nutrient Supplements (LNS):
Description: LNS are 20 g/\~110 calorie nutrient supplements that provide energy, protein, essential fatty acids and a wide range of micronutrients critical for children ages 6 to 24 months of age. They are designed to complement diets without displacing breastmilk and local dietary preferences and can be mixed into the child's meal or eaten directly from the sachet.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Growth Charts
Description: Growth charts have been locally developed to allow parents an easy assessment of their children's height at their home. Charts will be placed on walls inside homes and will provide parents the opportunity to measure their child whenever they want, and will also contain information on the most suitable local foods as well as the importance of diverse diets and frequent feeding.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Growth Charts
Description: Growth charts have been locally developed to allow parents an easy assessment of their children's height at their home. Charts will be placed on walls inside homes and will provide parents the opportunity to measure their child whenever they want, and will also contain information on the most suitable local foods as well as the importance of diverse diets and frequent feeding.
Study: NCT01689142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine new formulation (HOE901)
Description: Pharmaceutical form: solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine (HOE901)
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Study: NCT02911870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNAC
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNAC
Description: Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Oral administration
Study: NCT02727218

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest tube removal
Description: chest tube removal post thoracoscopic surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chest tube removal
Description: chest tube removal post thoracoscopic surgery